Get started
Author

Mónica A Romero-Riquelme

Observed names: Monica Alejandra Romero, Monica Romero‐Riquelme, Mónica A. Romero Riquelme, Mónica A. Romero-Riquelme, Mónica Alejandra Romero Riquelme
Observed institution: Hospital Regional de Concepción
ORCID: 0009-0004-1866-8831
Observed ORCID: 0009-0004-1866-8831
OpenAlex ID: A5119504166
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
2025 · Ana Alfonso-Pierola, David Martinez-Cuadrón, et al. · Leukemia · 3
Real‐World Outcomes of FLAG ‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML : A PETHEMA Study
2026 · Gaspar Aspas Requena, Rebeca Rodríguez‐Veiga, et al. · American Journal of Hematology · 1
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy
2026 · Bruno Paiva, Leire Burgos, et al. · Leukemia
Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3 ‐Mutated AML: The PETHRATIFY Study
2026 · Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, et al. · American Journal of Hematology
PDF
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry
2026 · Juan M. Alonso‐Dominguez, Tamara Castaño‐Bonilla, et al. · Cancer
Works count: 5
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type